CLINICAL_TRIALS
trial_result
· 2012-12-13
Clinical Trial Update: A 12-week Study of 4 Doses of VX-509 in Subjects With Active Rheumatoid Arthritis [Phase 2]
Summary
A Phase 2 clinical trial evaluating four doses of VX-509 in adults with active rheumatoid arthritis has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Vertex Pharmaceuticals Incorporated | Conditions: Rheumatoid Arthritis | Phase 2 | Status: COMPLETED